Senectus Therapeutics has signed a deal to screen a selection of AstraZeneca’s chemical compound library to identify those which trigger a key element of cancer cell ageing – called senescence. Senescent cells are those which after many rounds of cell growth and division enter a ‘sleep’ phase where the normal cell cycle is stopped. This blocks the uncontrolled growth and division of cells. It is a natural mechanism to prevent cancer. But cancer cells find ways to trick their way past this block and continue to grow and divide. Understanding the triggers to cell ageing may reveal molecular targets for completely new ways to treat cancer.
23 March, 2011
Metabolon, Inc., announces the publication of “Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome”, in The Proceedings of the National Academy of Sciences (PNAS 108 (8) 3270-3275).
03 March, 2011